THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...
“We are implementing a strategic realignment of Lexicon around some truly compelling assets, with a focus on LX9211 for neuropathic pain and other early-stage research and development programs,” said ...
9d
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 ...
THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development ...
Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon ”) today announced that it has commenced an underwritten public offering to offer and ...
INVUS TO INVEST $205 MILLION IN COMMON STOCK AT SIGNIFICANT PREMIUM SYMPHONY TO FUND ADDITIONAL $60 MILLION TO ADVANCE FIRST THREE DRUGS THE WOODLANDS, Texas, June 17 ...
Invus could invest up to $550 million, and Lexicon will provide $60 million to Symphony, created to develop Lexicon’s first three candidates. Lexicon Pharmaceuticals inked a $60-million deal with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results